Researchers from Belgium analyzed the transcriptomes of almost 100,000 single cells from lung cancer patients, most of them stromal cells.
The deal gives Biodesix an additional test in the lung cancer space, Indi's XL2, which helps to classify lung nodules identified by imaging scans as benign or malignant.
The grant will support the consortium's ongoing efforts to clinically validate data analysis software for monitoring treatment responses to cancer vaccines.
Two new studies have uncovered expression-defined T cell subsets that seem to coincide with better or worse outcomes in breast cancer or non-small cell lung cancer.
The firm has developed a new classifier for bladder cancer and continues to work with pharma companies in the lung cancer space.
With sequence data for more than 118,000 tumors profiled at Foundation Medicine, investigators tracked PDL1 amplification prevalence and possible treatment implications.
New tumor profiling papers stemming from prior clinical trials led to informative mutations in early-stage, ER+/HER2- breast cancer and lung squamous cell carcinoma.
As part of the collaboration, Johnson & Johnson will build a lung cancer center at Boston University and build upon programs linked to cancer research.
Though there are few direct hints at how the company plans to translate its findings to a clinical test, its early data has captured the attention of the cancer community.
New trial data presented at ASCO highlights the utility of checkpoint inhibitors, alone or with chemotherapy, across PD-L1 expression groups.
A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.
The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.
Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.
In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.